3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
363
Precursor Cell Lymphoblastic Leukemia-Lymphoma
89
Leukemia
61
Neoplasms, Plasma Cell
60
Lymphoma
59
Recurrence
52
Neoplasms
34
Vomiting
33
Lymphoma, Non-Hodgkin
32
Immunoglobulin Light-chain Amyloidosis
27
Lymphoma, Mantle-Cell
26
Burkitt Lymphoma
26
Nausea
22
Lymphoma, Large B-Cell, Diffuse
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Waldenstrom Macroglobulinemia
19
Prostatic Neoplasms
19
Lymphoma, Follicular
18
Hodgkin Disease
18
Neoplasm Metastasis
14
Breast Neoplasms
14
Amyloidosis
12
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Myeloid, Acute
11
Carcinoma, Non-Small-Cell Lung
11
Ovarian Neoplasms
9
Lymphoma, Large-Cell, Immunoblastic
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Cutaneous
8
Colonic Neoplasms
8
Interventions
Paclitaxel
4
Carboplatin
4
Pemetrexed
2
Palliative Care
2
Gemcitabine
2
temsirolimus
1
rucaparib
1
pembrolizumab
1
niraparib
1
nintedanib
1
nilotinib
1
liposomal doxorubicin
1
fosaprepitant
1
atezolizumab
1
argatroban
1
Topotecan
1
Thrombopoietin
1
Palonosetron
1
Ocoxin
1
Laparoscopy
1
Heparin, Low-Molecular-Weight
1
Filgrastim
1
Electrocardiography
1
Educational Status
1
Dexamethasone
1
Darbepoetin alfa
1
Cognitive Behavioral Therapy
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Genital Neoplasms, Female
×
Dexamethasone
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled